
    
      The study hypothesis is that the 5 year survival rate will reach 35% from 25% when
      neoadjuvant chemotherapy is carried out. With the alpha value to be 0.05 and beta value to be
      0.80 as well as 10 percent of patients' lost-of-followup, the sample size will be 263.
    
  